A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor

Background: Chimeric antigen receptor (CAR) T-cell therapy is practical in treating cancers of hematopoietic origin, but of that in solid tumors compromises efficacy for the loss of the antigen recognized by the CAR. However, dendritic cell (DC)/tumor fusion vaccines present a spectrum of known or u...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Shuyang, Ding, Ziqiang, Gao, Li, Hammock, Bruce D., Huang, Xianing, Xu, Zhi Ping, Wang, Xuan, Cheng, Qihong, Mo, Fengzhen, Shi, Wei, Xie, Shenxia, Liu, Aiqun, Li, Haixia, Yang, Xiaomei, Lu, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526666/
https://www.ncbi.nlm.nih.gov/pubmed/37771772
http://dx.doi.org/10.7150/thno.84946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526666/
https://www.ncbi.nlm.nih.gov/pubmed/37771772
http://dx.doi.org/10.7150/thno.84946

Ejemplares similares